I don’t see cardiac tissue adding much value to share price. My reasoning is simple. The only cost center generating cash flow seems to be the BioGlue cost center. I think that the cardiac tissue cost center operating margin is so low, that after subtracting the related operating expenses the tissue cost center has an operating loss. I don’t expect this to change. CRY has never, to my knowledge/recollection, ever said this cost center is currently profitable. CRY is welcome to comment on the subject if they wish.
Dirty lab and a liability tail? Not likely, but the probability is not zero either. So why take the risk when this cost center is just a gerbil wheel?
Conclusion: Draw your own conclusions. The above is just what I’m thinking about at this time. You Amigo have to sort things out for yourself. You are responsible for doing your own due diligence.